Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor receptor superfamily member 10B (TRAIL receptor 2) (TNFRSF10B (also known as DR5 or TRAIL-R2))
- Target
- TNFRSF10B (also known as DR5 or TRAIL-R2)
- Molecular classification
- Receptor, Tumor necrosis factor receptor superfamily (TNFRSF), Death receptor (contains an intracellular death domain)
01
Overview
Tumor necrosis factor receptor superfamily member 10B is a cell-surface death receptor of the TNF receptor superfamily that binds the ligand TRAIL (TNFSF10) to transmit apoptotic signals through its intracellular death domain. Upon activation, DR5 recruits the adaptor FADD and initiator caspases (caspase-8/10) to form the death-inducing signaling complex, leading to extrinsic apoptosis. It is therapeutically targeted in oncology with agonist antibodies and TRAIL or TRAIL-mimetic approaches.
- Other names
- Death receptor 5 (DR5)TRAIL receptor 2 (TRAIL-R2, TRAILR2)Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)CD262KILLERTRICK2ATRICKB
02
Mechanism of action
Agonist antibodies or TRAIL mimetics activate DR5, recruit FADD, and trigger caspase-8–mediated extrinsic apoptosis via DISC formation. TRAIL ligand binding to DR5 induces receptor trimerization and downstream apoptotic signaling.
03
Biological functions
Apoptosis induction via binding TRAIL (TNFSF10) and forming the death-inducing signaling complex (DISC)Signal transduction through adaptor FADD and initiator caspases (caspase-8, caspase-10)Immune response/tumor surveillance roles through TRAIL-mediated cytotoxic signaling
04
Disease associations
Cancer (therapeutic targeting; expression and regulation implicated in tumor cell apoptosis and resistance)Inflammation/immune pathways via TNF/TRAIL axis (context of TNF family signaling)
05
Safety considerations
On-target toxicity potential in normal tissues expressing DR5 (historically a consideration in clinical development of DR5 agonists)Variable efficacy due to tumor resistance mechanisms (e.g., low DR5 expression or defects in downstream apoptotic machinery)
06
Interacting drugs
Tigatuzumab (CS-1008)
1 more in the full profile.
07
Biomarkers
DR5 (TNFRSF10B) expression level as a potential predictor of response to TRAIL/DR5 agonists in tumorsTRAIL pathway components (e.g., FADD, caspase-8) as context biomarkers for apoptotic competence
Beyond the preview
Go deeper on Tumor necrosis factor receptor superfamily member 10B (TRAIL receptor 2) (TNFRSF10B (also known as DR5 or TRAIL-R2)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 10B (TRAIL receptor 2) (TNFRSF10B (also known as DR5 or TRAIL-R2)).